Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded ...

Colonoscopy prevalence increased from 19.5% in 2019 and 17.8% in 2021 to 27.7% in 2023, while stool-based testing increased ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives ...

University research in Wisconsin led to $500 million Third Wave business, screening tests for cancer, including Cologuard ...

After months of silence, Darksiders 4 is finally coming out of the shadows. During the THQ Nordic show, we received the first ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

Review quarterly and annual revenue, net income, and cash flow for Exact Sciences Corp (EXAS:XNAS) stock through the last fiscal year.